Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 232

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

A Randomized, Placebo-Controlled Study of the Effects of Denosumab for the Treatment of Men with Low Bone Mineral Density

Orwoll, Eric, Teglbjærg, Christence S., Langdahl, Bente L., Chapurlat, Roland, Czerwinski, Edward, Kendler, David L., Reginster, Jean-Yves, Kivitz, Alan, Lewiecki, E. Michael, Miller, Paul D., Bolognese, Michael A., McClung, Michael R., Bone, Henry G., Ljunggren, Östen, Abrahamsen, Bo, Gruntmanis, Ugis, Yang, Yu-Ching, Wagman, Rachel B., Siddhanti, Suresh, Grauer, Andreas, Hall, Jesse W., Boonen, Steven · 2012 · The Journal of Clinical Endocrinology & Metabolism

Abstract

CONTEXT: Men with low bone mineral density (BMD) were treated with denosumab. OBJECTIVE: Our objective was to investigate the effects of denosumab compared with placebo in men with low BMD after 1 yr of treatment. DESIGN, SUBJECTS, AND INTERVENTION: This was a placebo-controlled, phase 3 study to investigate the efficacy and safety of denosumab 60 mg every 6 months vs. placebo in men with low BMD. MAIN OUTCOME MEASURE: The primary endpoint was the percent change from baseline in lumbar spine (LS) BMD at month 12. RESULTS: Of the 242 randomized subjects (mean age 65 yr), 228 (94.2%) completed 1 yr of denosumab therapy. After 12 months, denosumab resulted in BMD increases of 5.7% at the LS, 2.4% at the total hip, 2.1% at the femoral neck, 3.1% at the trochanter, and 0.6% at the one third radius (adjusted P ≤ 0.0144 for BMD percent differences at all sites compared with placebo). Sensitivity analyses done by controlling for baseline covariates (such as baseline testosterone levels, BMD T-scores, and 10-yr osteoporotic fracture risk) demonstrated that the results of the primary endpoint were robust. Subgroup analyses indicate that treatment with denosumab was effective across a spectrum of clinical situations. Treatment with denosumab significantly reduced serum CTX levels at d 15 (adjusted P < 0.0001). The incidence of adverse events was similar between groups. CONCLUSIONS: One year of denosumab therapy in men with low BMD was well tolerated and resulted in a reduction in bone resorption and significant increases in BMD at all skeletal sites assessed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2012-1569

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 232

Metadata

Authors
Orwoll, E., Teglbjærg, C. S., Langdahl, B. L., Chapurlat, R., Czerwinski, E., Kendler, D. L., Reginster, J.-Y., Kivitz, A., Lewiecki, E. M., Miller, P. D., Bolognese, M. A., McClung, M. R., Bone, H. G., Ljunggren, Ö., Abrahamsen, B., Gruntmanis, U., Yang, Y.-C., Wagman, R. B., Siddhanti, S., Grauer, A., Hall, J. W., & Boonen, S.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2012-09-01
Volume
97
Issue
9
Pages
3161-3169
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2166145588
Cited by
232
References
3
FWCI
21.81
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Randomized, Placebo-Controlled Study of the Effects of Denosumab for the Treatment of Men with Low Bone Mineral Density. https://app.cochat.ai/papers/10.1210/jc.2012-1569
The paper
Orwoll, E., Teglbjærg, C. S., Langdahl, B. L., Chapurlat, R., Czerwinski, E., Kendler, D. L., Reginster, J.-Y., Kivitz, A., Lewiecki, E. M., Miller, P. D., Bolognese, M. A., McClung, M. R., Bone, H. G., Ljunggren, Ö., Abrahamsen, B., Gruntmanis, U., Yang, Y.-C., Wagman, R. B., Siddhanti, S., . . . Boonen, S. (2012). A Randomized, Placebo-Controlled Study of the Effects of Denosumab for the Treatment of Men with Low Bone Mineral Density. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2012-1569

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.